Development of candidemia on caspofungin therapy

A case report

C. Cheung, Y. Guo, Philip Gialanella, M. Feldmesser

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Caspofungin, an echinocandin, is approved for use in invasive candidiasis. Few cases of break-through candidal infections during caspofungin therapy have been reported and none have involved Candida parapsilosis. Here, we report a patient who developed multiple post-operative complications after pancreaticoduodenectomy for a pancreatic mass, including fungemia due to C. parapsilosis, while on caspofungin for treatment of Candida glabrata peritonitis. The fungemia resolved after a central venous catheter was removed and therapy was switched from caspofungin to amphotericin B lipid complex. Studies of C. parapsilosis susceptibility and the pharmacodynamics and drug interactions of caspofungin that may contribute to breakthrough fungemia are discussed.

Original languageEnglish (US)
Pages (from-to)345-348
Number of pages4
JournalInfection
Volume34
Issue number6
DOIs
StatePublished - Dec 2006

Fingerprint

caspofungin
Candidemia
Fungemia
Invasive Candidiasis
Echinocandins
Candida glabrata
Therapeutics
Pancreaticoduodenectomy
Central Venous Catheters
Peritonitis
Drug Interactions
Candida
Infection

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Cite this

Development of candidemia on caspofungin therapy : A case report. / Cheung, C.; Guo, Y.; Gialanella, Philip; Feldmesser, M.

In: Infection, Vol. 34, No. 6, 12.2006, p. 345-348.

Research output: Contribution to journalArticle

Cheung, C. ; Guo, Y. ; Gialanella, Philip ; Feldmesser, M. / Development of candidemia on caspofungin therapy : A case report. In: Infection. 2006 ; Vol. 34, No. 6. pp. 345-348.
@article{0f0bcede782c42829d03f51cb514e511,
title = "Development of candidemia on caspofungin therapy: A case report",
abstract = "Caspofungin, an echinocandin, is approved for use in invasive candidiasis. Few cases of break-through candidal infections during caspofungin therapy have been reported and none have involved Candida parapsilosis. Here, we report a patient who developed multiple post-operative complications after pancreaticoduodenectomy for a pancreatic mass, including fungemia due to C. parapsilosis, while on caspofungin for treatment of Candida glabrata peritonitis. The fungemia resolved after a central venous catheter was removed and therapy was switched from caspofungin to amphotericin B lipid complex. Studies of C. parapsilosis susceptibility and the pharmacodynamics and drug interactions of caspofungin that may contribute to breakthrough fungemia are discussed.",
author = "C. Cheung and Y. Guo and Philip Gialanella and M. Feldmesser",
year = "2006",
month = "12",
doi = "10.1007/s15010-006-5613-7",
language = "English (US)",
volume = "34",
pages = "345--348",
journal = "Infection",
issn = "0300-8126",
publisher = "Urban und Vogel",
number = "6",

}

TY - JOUR

T1 - Development of candidemia on caspofungin therapy

T2 - A case report

AU - Cheung, C.

AU - Guo, Y.

AU - Gialanella, Philip

AU - Feldmesser, M.

PY - 2006/12

Y1 - 2006/12

N2 - Caspofungin, an echinocandin, is approved for use in invasive candidiasis. Few cases of break-through candidal infections during caspofungin therapy have been reported and none have involved Candida parapsilosis. Here, we report a patient who developed multiple post-operative complications after pancreaticoduodenectomy for a pancreatic mass, including fungemia due to C. parapsilosis, while on caspofungin for treatment of Candida glabrata peritonitis. The fungemia resolved after a central venous catheter was removed and therapy was switched from caspofungin to amphotericin B lipid complex. Studies of C. parapsilosis susceptibility and the pharmacodynamics and drug interactions of caspofungin that may contribute to breakthrough fungemia are discussed.

AB - Caspofungin, an echinocandin, is approved for use in invasive candidiasis. Few cases of break-through candidal infections during caspofungin therapy have been reported and none have involved Candida parapsilosis. Here, we report a patient who developed multiple post-operative complications after pancreaticoduodenectomy for a pancreatic mass, including fungemia due to C. parapsilosis, while on caspofungin for treatment of Candida glabrata peritonitis. The fungemia resolved after a central venous catheter was removed and therapy was switched from caspofungin to amphotericin B lipid complex. Studies of C. parapsilosis susceptibility and the pharmacodynamics and drug interactions of caspofungin that may contribute to breakthrough fungemia are discussed.

UR - http://www.scopus.com/inward/record.url?scp=33845711367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845711367&partnerID=8YFLogxK

U2 - 10.1007/s15010-006-5613-7

DO - 10.1007/s15010-006-5613-7

M3 - Article

VL - 34

SP - 345

EP - 348

JO - Infection

JF - Infection

SN - 0300-8126

IS - 6

ER -